Geisinger Member Update

Mental health and substance abuse network update

Effective July 1, 2016, we are making changes to our network of mental health and substance abuse providers. We have selected Magellan Healthcare, Inc. to provide mental health and substance abuse services as covered by your plan. Magellan offers a broad network of experienced providers, and nurse case managers who will work with GHP staff to provide you care. Magellan's valuable online extras, such as their web-based learning programs, will provide additional resources.

Some providers may no longer be in the network. Members who are being seen by the affected providers will be notified by letter and given further instruction regarding their transition of care. To verify whether a provider is part of the new network, please **visit mgln.us/GHPprovidersearch**. Magellan will continue to add providers on an ongoing basis, so please visit frequently to view the most updated list.

If you have any questions, or would like additional information or assistance, please contact Magellan at (800) 424-4701 (TDD/TTY: 711) from 9:00 a.m. – 6:30 p.m. After July 1, 2016, please contact Magellan using the phone number listed on the back of your member identification card.



In this issue

New physicians2	2
Formulary updates	3
Geisinger's new research study4	1

The Member Update is published quarterly by Geisinger Health Plan and serves as an informational resource for members.

Comments are welcomed. Email: memberupdate@thehealthplan.com.

Geisinger Health Plan may refer collectively to Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted.

HPM50 GHP MU Summer 2016 Photo credits: iStock/Thinkstock

New physicians

This list includes new primary care physicians (PCPs) who have joined our network since April 2016. For more information on these and other participating providers, please visit TheHealthPlan.com, or call the customer service team at the number on the back of your member ID card.

(Key: FP, Family Practice; IM, Internal Medicine; and P, Pediatrics)



Allegheny

Crawford Faucher MD, Amy D. - FP Schwab DO, Brian Richard - FP Talarico MD, Ashley Victoria - FP Thomas DO, Kevin Albert - FP Ciuksza MD, Mallory Strickland - FP Frank MD, Janine Michelle - FP Haddad MD, Abdullah - FP Lamb DO, Brian Michael - FP Speredelozzi MD, Daniel Paul - IM Ternullo MD, Damian Lee - P

Berks

Arias MD, Felipe Antonio - FP Buch MD, Sandhya Y. - FP Pepen MD, Lazaro - FP

Blair

Delozier MD, Levi Nicholas - FP Froncillo DO, Anthony J. - FP Punjani MD, Perveen A.B. - P

Butler

Lin MD, Kirsten - FP Srivastava DO, Apoorva - IM

Centre

Bondalapati MD, Navatha - FP Alexander MD, Cynthia D. - FP

Dauphin Davis MD, Lisa M. - FP

Delaware Munshower DO, John C. - FP

Huntingdon Holmes DO, Allison Buza - FP

Lackawana Giddings Connolly MD, Christopher

Andre - FP

Lehigh Shustik MD, Miriam - FP

Luzerne Yusko CRNP, Darnetta - FP

Mercer Sawardekar MD, Arun Sazro - P Mifflin Holmes DO, Allison Buza - FP

Monroe Giddings Connolly MD, Christopher Andre - FP

Montgomery Cooper MD, Barbara A. - IM

Northampton Carnathan MD, Michael J. - FP

Philadelphia Shiau MD, Tiffany W. - IM

Washington Friedsam MD, Patricia L. - IM

Westmoreland Dugan MD, Courtney Noelle - FP Teitelbaum DO, Miriam L. - FP

York Zubrod MD, Gordon Joshua - FP Yoo MD, Heui G. - IM

Formulary updates

The table below represents recent updates to the formulary. If you have any questions, please contact the pharmacy customer service team at (800) 988-4861, Monday through Friday, 8 a.m. to 5 p.m. Obtain a hard copy of the formulary by calling customer service or logging on to TheHealthPlan.com. (Non Formulary = NF; Formulary = F)

Non-Marketplace plans —										
Brand Name	Status	Market- place Tier	Triple Tier Formulary	4th Tier Applicable	Traditional Formulary	Prior Auth	Qty Limit	Detailed Limits	Formulary Alternatives	
ADDYI	NF	NF	NF	No	NF	Yes	Yes	1 tablet per day	none	
ALECENSA	F	5	3	Yes	2	Yes	Yes	8 capsules per day, 30 day supply per fill	Zykadia*	
ENOXAPARIN	F	2	1	Yes	1	No	Yes	30 day supply per fill	none	
GUANFACINE ER	F	2	1	No	1	No	No	-	-	
PRALUENT	F	3	2	No	2	Yes	Yes	2 mL per 28 days	atorvastatin, rosuvastatin, Zetia, Welchol, cholestyramine, colestipol	
SEEBRI NEOHALER	NF	NF	NF	No	NF	Yes	No	-	Spiriva HandiHaler, Spiriva Respimat	
STRENSIQ	F	5	3	Yes	2	Yes	Yes	30 day supply per fill	none	
TOBRAMYCIN INHALATION SOLUTION	F	2	1	No	1	Yes	Yes	56 vials per 56 days	none	
TRESIBA	NF	NF	NF	No	NF	Yes	No	-	Lantus, Levemir, Toujeo	
UTIBRON NEOHALER	NF	NF	NF	No	NF	Yes	No	-	Anoro Ellipta	
VARUBI	F	3	3	No	2	No	Yes	2 tablets per 14 days	Emend (quantity limits apply)	
VIBERZI	NF	NF	NF	No	NF	Yes	Yes	2 tablets per day	alosetron, dicyclomine, diphenoxylate-atropine, loperamide	
ZOLPIDEM CR	F	2	1	No	1	No	No	-	zolpidem, zaleplon	

—Non-Marketplace plans ——

* Indicates prior authorization (PA) or step therapy (ST)

Notable updates

The copay per 15 day supply limitation has been lifted from the following medications: Adcirca / Afinitor / Eszopiclone / Exjade / Intermezzo / Nexavar / Rozerem / Sonata / Sprycel / Sutent / Tasigna / Tracleer / Tyvaso / Votrient / Zaleplon / Zolpidem / Zolpidem CR

The following medications for the treatment of human immunodeficiency virus (HIV) have been moved to the brand preferred tier: Edurant / Fuzeon / Reyataz / Stribild / Tivicay / Triumeq / Viread



100 N. Academy Ave. Danville, PA 17822-3240 NON-PROFIT ORG. U.S. POSTAGE PAID Geisinger

Geisinger begins new research study

Dr. Christopher Still, Director of the Obesity Institute, along with Dr. Michael Suk, Director of the Orthopaedics Institute, and Dr. Anthony Petrick, Director of the Minimally Invasive and Bariatric Surgery Department, are studying the effect that weight loss (bariatric) surgery has on total knee replacement (arthroplasty) surgery outcomes. You may be eligible for this study if you are in need of total knee replacement surgery. Patients who need knee replacement surgery are often advised to lose weight before surgery and may choose to do so through bariatric surgery. In this study, they will follow patients who have total knee replacement surgery and patients who have bariatric surgery before their total knee replacement surgery.

Your participation will not affect your insurance or care at any of the Geisinger Clinics or at the medical center. If you choose to participate, you will be compensated for your time and travel.

If you would like to discuss the study in more detail, please call (570) 214-2721. Please reference study #2015-0244 when calling. If you have questions about your rights as a participant, please call the Geisinger Institutional Review Board (IRB) at (570) 271-8663 identifying study #2015-0244.